The approval is supported by results from the Phase III TULIP-SC trial.

AstraZeneca plc (NASDAQ:AZN) has been granted approval by the U.S. Food and Drug Administration for a new self-injection ...

Drugmaker AstraZeneca said on Tuesday that it asthma maintenance treatment Breztri Aerosphere had received approval from the ...

AstraZeneca PLC on Monday said its self-administered lupus treatment has been approved in the US. The US Food & Drug ...

AstraZeneca’s SAPHNELO ® (anifrolumab-fnia) has been approved in the US for self-administration as a once-weekly autoinjector, the SAPHNELO Pen , for the treatment of adult patients with systemic ...

AstraZeneca plc (LSE:AZN) has received approval from the U.S. Food and Drug Administration for a new self-administered ...

OPEN The FTSE 100 was expected to open just 0.3 points higher ahead of the bell on Monday, after wrapping up the previous session 0.75% lower at 10,379.08.

AstraZeneca has secured approval in the US for Calquence (acalabrutinib) plus venetoclax as the first all-oral, fixed-duration regimen to treat adults with chronic lymphocytic leukaemia (CLL) and ...

Detailed price information for Astrazeneca Plc Ord (AZNCF) from The Globe and Mail including charting and trades.

AstraZeneca’s fixed-dose triple-combination therapy BREZTRI Aerosphere® (budesonide/glycopyrrolate/formoterol fumarate or BGF 320/36/9.6μg) has been approved in the US for the maintenance treatment of ...

AstraZeneca’s Saphnelo approved in US for subcutaneous self-administration as a new autoinjector to treat systemic lupus erythematosus: Cambridge, UK Tuesday, April 28, 2026, 10 ...